Manufacturing Expansion, Bio-fermenter - Biocogent
With the help of: New York Manufacturing Extension Partnership (NY MEP)
About
Biocogent, LLC was founded in 2010, and is located in the Long Island High Tech Incubator (LIHTI) Center. They are a biotechnology company focusing on research, development and manufacture of skin-active materials used in specialized skin care products in both the personal care and med-care markets.Cell and Molecular Biology, synthetic and nucleic acid chemistry, and fermentation are strategic technical resources at Biocogent. Utilizing over 100 years of cumulative expertise in skin, cell and tissue culture, and biochemistry, they have established themselves as a leader in the understanding of therapeutic indicators for skin treatment products. Their laboratories are equipped to perform everything from standard cell and tissue model assays to custom developed unique bio-assays for specific targets and indicators.
The Challenge
Much of the product development performed at Biocogent is based in bio-conversion and bio-fermentation. This platform was identified as a direct path for commercializing products resulting from the research and development of treatment moieties based on complex and pleiotropic bio-molecules. The need for additional bio-fermenter capacity was crucial to keep up with the development of new products and the increase in demand of Biocogent’s products. Biocogent also needed a chemical engineer to run the biofermenter to support this method and increase productivity. MTRC assisted by providing funding along with their program partners to help in lowering the costs involved in this project, making Biocogent more competitive in domestic and global markets.
"It is a pleasure to work with the MTRC staff at Stony Brook. They are keenly aware of the challenges facing start-up and emerging companies and were very helpful shepherding Biocogent through the application process."— Joseph Ceccoli, President, Biocogent
MEP's Role
MTRC was able to support the project with a supplemental award. This provided Biocogent the capital to purchase the additional bio-fermenter and support the increase in volume production and capacity. The increase in production capability has lead to an increase in commercial capacity and in the quality of their product resulting in an increase in sales. The added capacity and process controls (quality) has allowed Biocogent to pursue additional business opportunities with key global customers.
